Merrill Lowers Taro Pharmaceutical to Neutral

Analyst Gregory Gilbert downgraded the drugmaker following its surprise earnings shortfall

Merrill Lynch downgraded Taro Pharmaceutical (TARO ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.